

ASTRAZENECA PLC
Form 6-K
March 28, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of (March 2018)

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82- _____

AstraZeneca PLC

INDEX TO EXHIBITS

Director/PDMR Shareholding

28 March 2018 15:00 BST

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 27 March 2018, awards of the Company's ordinary shares of \$0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP).

The AZDBP award was granted on 27 March 2015, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2014 performance into Ordinary Shares, and vested on completion of the three-year holding period.

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:

| PDMR | Ordinary Shares acquired under the AZDBP |
|---------------|--|
| Pascal Soriot | 11,998 |
| Marc Dunoyer | 3,768 |

For tax purposes, the fair market value of an Ordinary Share at vest was 4760.0 pence, being the closing price on the last trading day preceding the vesting day.

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations

| | | |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 203 749 5638 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Matt Kent | UK/Global | +44 203 749 5906 |
| Gonzalo Viña | UK/Global | +44 203 749 5916 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Relations

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | |
|---------------------|----------------------------|------------------|
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Craig Marks | Finance; Fixed Income; M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology; Other | +1 240 477 3771 |
| Christer Gruvris | Brilinta; Diabetes | +44 203 749 5711 |
| Nick Stone | Respiratory; Renal | +44 203 749 5716 |
| US toll free | | +1 866 381 7277 |

Adrian Kemp
 Company Secretary
 AstraZeneca PLC

- 1 Details of the person discharging managerial responsibilities / person closely associated
- a) Name Pascal Soriot
- 2 Reason for the notification
- a) Position/status Chief Executive Officer
- b) Initial notification /Amendment Initial notification
- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name AstraZeneca PLC
- b) LEI PY6ZZQWO2IZFZC3IOL08
- 4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
- a) Description of the financial instrument, type of instrument Ordinary Shares of US\$0.25
each in AstraZeneca PLC
- Identification code GB0009895292
- b) Nature of the transaction Acquisition of ordinary shares
pursuant to a vesting under
the AstraZeneca Deferred
Bonus Plan, for nil
consideration.
- c) Price(s) and volume(s) Price(s) Volume(s)
0 11,998
- d) Aggregated information Not applicable - single
transaction
- Aggregated volume
- Price

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | |
|----|---|--|
| e) | Date of the transaction | 27 March 2018 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Marc Dunoyer |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | AstraZeneca PLC |
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 |
| 4i | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of US\$0.25 each in AstraZeneca PLC |
| | Identification code | GB0009895292 |
| b) | Nature of the transaction | Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Deferred Bonus Plan, for nil consideration. |
| c) | Price(s) and volume(s) | Price(s) Volume(s) 0 3,768 |
| d) | Aggregated information | Not applicable - single transaction |
| | - Aggregated volume | |
| | - Price | |
| e) | Date of the transaction | 27 March 2018 |
| f) | Place of the transaction | Outside a trading venue |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 March 2018

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary